This is a Validated Antibody Database (VAD) review about rat Pias4, based on 6 published articles (read how Labome selects the articles), using Pias4 antibody in all methods. It is aimed to help Labome visitors find the most suited Pias4 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Pias4 synonym: E3 SUMO-protein ligase PIAS4
Santa Cruz Biotechnology
mouse monoclonal (C-11) |
| Santa Cruz Biotechnology Pias4 antibody (Santa Cruz, sc-166706) was used in immunohistochemistry - paraffin section on mouse samples at 1:200 (fig 3c) and in immunohistochemistry - paraffin section on human samples at 1:200 (fig 3d). Sci Rep (2016) ncbi |
mouse monoclonal (F-9) |
| Santa Cruz Biotechnology Pias4 antibody (Santa Cruz Biotechnology, sc-166744) was used in western blot on human samples (fig 3e). Nucleic Acids Res (2015) ncbi |
Proteintech Group
rabbit polyclonal |
| Proteintech Group Pias4 antibody (Proteintech, 14242-1-AP) was used in western blot on human samples at 1:1000 (fig 7c). Nat Commun (2016) ncbi |
MilliporeSigma
rabbit polyclonal |
| MilliporeSigma Pias4 antibody (Sigma-Aldrich, AV33011) was used in western blot on human samples at 1:1000 (fig s8a). Nat Commun (2018) ncbi |
Cell Signaling Technology
rabbit monoclonal (D2F12) |
| In order to investigate the oncogenic effect of miR-210-3p in prostate cancer and bone metastasis and its mechanism, Cell Signaling Technology Pias4 antibody (cell signalling, 4392) was used in western blot on human samples (fig 4b). Mol Cancer (2017) ncbi |
rabbit monoclonal (D2F12) |
| Cell Signaling Technology Pias4 antibody (Cell Signaling, 4392) was used in western blot on rat samples at 1:1000 (fig s2a). Cell Death Differ (2017) ncbi |
Articles Reviewed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments